Emalex Biosciences
Chicago
About Emalex Biosciences
Emalex Biosciences is a biotech startup that develops new treatments for central nervous system disorders. The company's first development candidate Ecopipam, is a novel compound that has been studied as a potential treatment for many central nervous system (CNS) disorders, including pediatric Tourette Syndrome. Emalex Biosciences was founded in 2018 by Jeff Aronin.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $320.0M
- Funding stage: Late Stage Venture
- Last round: Series D (Nov 2022)
- Website: emalexbiosciences.com
- Phone: +1 312-847-1340
Industries & Categories
Biopharma, Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/emalex-biosciences-92997 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.